Download PDF
Semin Liver Dis 2005; 25(1): 18-32
DOI: 10.1055/s-2005-864779
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Management and Treatment of Injection Drug Users with Hepatitis C Virus (HCV) Infection and HCV/Human Immunodeficiency Virus Coinfection

Gregory J. Dore1 , David L. Thomas2
  • 1Associate Professor and Head, Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, and Infectious Diseases Physician, HIV/Immunology/Infectious Diseases Clinical Services Unit, St. Vincent's Hospital, Darlinghurst, Australia
  • 2Professor of Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
Further Information

Publication History

Publication Date:
25 February 2005 (online)

    Permissions and Reprints

ABSTRACT

Injection drug use is the major mode of hepatitis C virus (HCV) transmission in developed countries. Despite this, relatively few current and recovering injection drug users (IDUs) have received HCV treatment. Studies among individuals with a recent history of injection drug use or those receiving drug dependency treatment have provided evidence that these groups can be successfully treated for chronic HCV infection. These studies have provided the impetus to change guidelines for treatment of current and recovering IDUs, with a move toward individualized HCV treatment assessment and the removal of defined periods of illicit drug use abstinence. Strategies to improve access to HCV treatment for current and recovering IDUs include drug dependency treatment education and training for hepatologists and other HCV treatment physicians, HCV treatment education and training for addiction medicine physicians, development of multidisciplinary clinics, and peer-based eduction and support for individuals considering and receiving HCV treatment.

KEYWORDS

Hepatitis C - HIV/HCV coinfection - injection drug users

REFERENCES

  • 1 Wasley A, Alter M J. Epidemiology of hepatitis C: geographic differences and temporal trends.  Semin Liver Dis. 2000;  20 1-16
    PubMedGoogle Scholar
  • 2 Dore G J, Law M, MacDonald M, Kaldor J M. Epidemiology of hepatitis C virus infection in Australia.  J Clin Virol. 2003;  26 171-184
    CrossrefPubMedGoogle Scholar
  • 3 Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature.  Epidemiol Infect. 2002;  129 577-585
    PubMedGoogle Scholar
  • 4 Steffen T, Blattler R, Gutzwiller F, Zwahlen M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme.  Eur J Public Health. 2001;  11 425-430
    PubMedGoogle Scholar
  • 5 Hagan H, Des Jarlais D C. HIV and HCV infection among injecting drug users.  Mt Sinai J Med. 2000;  67 423-428
    PubMedGoogle Scholar
  • 6 McCarthy J J, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications.  J Addict Dis. 2001;  20 19-31
    CrossrefPubMedGoogle Scholar
  • 7 Garfein R S, Doherty M C, Monterroso E R, Thomas D L, Nelson K E, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users.  J Acquir Immune Defic Syndr Hum Retrovirol. 1998;  18(suppl 1) 11-19
    PubMedGoogle Scholar
  • 8 Quaglio G, Lugoboni F, Pajusco B et al.. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy.  Clin Infect Dis. 2003;  37 33-40
    CrossrefPubMedGoogle Scholar
  • 9 MacDonald M A, Wodak A D, Dolan K A, van Beek I, Cunningham P H, Kaldor J M. Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997. Collaboration of Australian NSPs.  Med J Aust. 2000;  172 57-61
    PubMedGoogle Scholar
  • 10 Thomas D L, Vlahov D, Solomon L et al.. Correlates of hepatitis C virus infections among injection drug users.  Medicine (Baltimore). 1995;  74 212-220
    CrossrefPubMedGoogle Scholar
  • 11 Law M G. Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group.  J Gastroenterol Hepatol. 1999;  14 1100-1107
    CrossrefPubMedGoogle Scholar
  • 12 National Institues of Health . Management of hepatitis C. NIH Consensus Statement 1997.  Available at:http://odp.od.nih.gov/consensus/cons/105/105_intro.htm , Accessed September 20 2004; 
    Google Scholar
  • 13 National Institutes of Health Consensus Development Conference Statement . Management of hepatitis C: June 10-12, 2002.  Hepatology. 2002;  36(suppl 1) S3-S20
    CrossrefPubMedGoogle Scholar
  • 14 Strader D B, Wright T, Thomas D L, Seeff L B. Diagnosis, management, and treatment of hepatitis C.  Hepatology. 2004;  39 1147-1171
    CrossrefPubMedGoogle Scholar
  • 15 Manns M P, McHutchison J G, Gordon S C et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965
    CrossrefPubMedGoogle Scholar
  • 16 Fried M W, Shiffman M L, Reddy K R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982
    CrossrefPubMedGoogle Scholar
  • 17 Poynard T, Marcellin P, Lee S S et al.. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).  Lancet. 1998;  352 1426-1432
    CrossrefPubMedGoogle Scholar
  • 18 McHutchison J G, Gordon S C, Schiff E R et al.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 1485-1492
    CrossrefPubMedGoogle Scholar
  • 19 Sylvestre D L. Treating hepatitis C in methadone maintenance patients: an interim analysis.  Drug Alcohol Depend. 2002;  67 117-123
    CrossrefPubMedGoogle Scholar
  • 20 Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users.  Hepatology. 2001;  34 188-193
    CrossrefPubMedGoogle Scholar
  • 21 Edlin B R. Prevention and treatment of hepatitis C in injection drug users.  Hepatology. 2002;  36(suppl 1) S210-S219
    CrossrefPubMedGoogle Scholar
  • 22 Hepatitis C infection and substance abuse: Medical management and developing models of integrative care.  Proc Clin Infect Dis. 2005;  40(suppl 5) , in press
    PubMedGoogle Scholar
  • 23 Stoove M A, Gifford S M, Dore G J. The impact of injecting drug use on hepatitis C-related referral and treatment.  Drug Alcohol Depend. 2005;  77 81-86
    PubMedGoogle Scholar
  • 24 Fleming C A, Craven D E, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment.  Clin Infect Dis. 2003;  36 97-100
    CrossrefPubMedGoogle Scholar
  • 25 Crofts N, Aitken C K. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990-1995.  Med J Aust. 1997;  167 17-20
    PubMedGoogle Scholar
  • 26 van Beek I, Dwyer R, Dore G J, Luo K, Kaldor J M. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.  BMJ. 1998;  317 433-437
    PubMedGoogle Scholar
  • 27 Hahn J A, Page-Shafer K, Lum P J et al.. Hepatitis C virus seroconversion among young injection drug users: relationships and risks.  J Infect Dis. 2002;  186 1558-1564
    CrossrefPubMedGoogle Scholar
  • 28 Crofts N, Hopper J L, Bowden D S, Breschkin A M, Milner R, Locarnini S A. Hepatitis C virus infection among a cohort of Victorian injecting drug users.  Med J Aust. 1993;  159 237-241
    PubMedGoogle Scholar
  • 29 NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2002. Sydney; National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales 2002
    Google Scholar
  • 30 Hagan H, McGough J P, Thiede H, Weiss N S, Hopkins S, Alexander E R. Syringe exchange and risk of infection with hepatitis B and C viruses.  Am J Epidemiol. 1999;  149 203-213
    PubMedGoogle Scholar
  • 31 MacDonald M, Law M, Kaldor J M, Hales J, Dore G J. Effectiveness of needle and syringe programmes for preventing HIV transmission.  Int J Drug Policy. 2003;  14 353-357
    PubMedGoogle Scholar
  • 32 Crofts N, Aitken C K, Kaldor J M. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not.  Med J Aust. 1999;  170 220-221
    PubMedGoogle Scholar
  • 33 Micallef J, Kaldor J, Dore G. Estimation of progression to chronic hepatitis C: a meta-analysis. Paper presented at: 11th International Symposium on Viral Hepatitis and Liver Disease in Sydney Australia; April 1 2003: 6-10
    Google Scholar
  • 34 Villano S A, Vlahov D, Nelson K E, Cohn S, Thomas D L. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection.  Hepatology. 1999;  29 908-914
    CrossrefPubMedGoogle Scholar
  • 35 Freeman A J, Dore G J, Law M G et al.. Estimating progression to cirrhosis in chronic hepatitis C virus infection.  Hepatology. 2001;  34(4 pt 1) 809-816
    CrossrefPubMedGoogle Scholar
  • 36 Dore G J, Freeman A J, Law M, Kaldor J M. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings.  Antivir Ther. 2003;  8 365-372
    PubMedGoogle Scholar
  • 37 Thomas D L, Astemborski J, Rai R M et al.. The natural history of hepatitis C virus infection: host, viral, and environmental factors.  JAMA. 2000;  284 450-456
    CrossrefPubMedGoogle Scholar
  • 38 Graham C S, Baden L R, Yu E et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.  Clin Infect Dis. 2001;  33 562-569
    CrossrefPubMedGoogle Scholar
  • 39 Goedert J J, Eyster M E, Lederman M M et al.. End-stage liver disease in persons with hemophilia and transfusion-associated infections.  Blood. 2002;  100 1584-1589
    PubMedGoogle Scholar
  • 40 Benhamou Y, Bochet M, Di Martino V et al.. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.  Hepatology. 1999;  30 1054-1058
    CrossrefPubMedGoogle Scholar
  • 41 Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.  Lancet. 1997;  349 825-832
    CrossrefPubMedGoogle Scholar
  • 42 Freeman A J, Law M G, Kaldor J M, Dore G J. Predicting progression to cirrhosis in chronic hepatitis C virus infection.  J Viral Hepat. 2003;  10 285-293
    CrossrefPubMedGoogle Scholar
  • 43 Gordon S C, Elloway R S, Long J C, Dmuchowski C F. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use.  Hepatology. 1993;  18 1338-1343
    CrossrefPubMedGoogle Scholar
  • 44 Rai R, Wilson L E, Astemborski J et al.. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users.  Hepatology. 2002;  35 1247-1255
    CrossrefPubMedGoogle Scholar
  • 45 Davis G L, Rodrigue J R. Treatment of chronic hepatitis C in active drug users.  N Engl J Med. 2001;  345 215-217
    PubMedGoogle Scholar
  • 46 Van Thiel D H, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.  Am J Gastroenterol. 2003;  98 2281-2288
    PubMedGoogle Scholar
  • 47 Schaefer M, Schmidt F, Folwaczny C et al.. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.  Hepatology. 2003;  37 443-451
    CrossrefPubMedGoogle Scholar
  • 48 Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance.  Hepatology. 2004;  40 120-124
    CrossrefPubMedGoogle Scholar
  • 49 Neri S, Bruno C M, Abate G et al.. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b.  Clin Ther. 2002;  24 1627-1635
    CrossrefPubMedGoogle Scholar
  • 50 Matthews G, Kronrborg I J, Dore G J. Treatment for hepatitis C virus current injection drug users in Australia.  Clin Infect Dis. 2005;  40(suppl 5) , in press
    PubMedGoogle Scholar
  • 51 Jaeckel E, Cornberg M, Wedemeyer H et al.. Treatment of acute hepatitis C with interferon alfa-2b.  N Engl J Med. 2001;  345 1452-1457
    CrossrefPubMedGoogle Scholar
  • 52 Kamal S M, Ismail A, Graham C S et al.. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.  Hepatology. 2004;  39 1721-1731
    CrossrefPubMedGoogle Scholar
  • 53 Alberti A, Boccato S, Vario A, Benvegnu L. Therapy of acute hepatitis C.  Hepatology. 2002;  36(suppl 1) 195-200
    CrossrefPubMedGoogle Scholar
  • 54 NCHECR. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2003. Sydney; National Centre in HIV Epidemiology and Clinical Research (NCHECR), The University of New South Wales 2003
    Google Scholar
  • 55 Doab A, Treloar C, Dore G J. Knowledge and attitude about treatment for hepatitis C virus infection, and barriers to treatment among current injection drug users in Australia.  Clin Infect Dis. 2005;  40(suppl 5) , in press
    PubMedGoogle Scholar
  • 56 Stein M D, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment.  Drug Alcohol Depend. 2001;  61 211-215
    PubMedGoogle Scholar
  • 57 Anti-Discrimination Board of New South Wales . C-change: the report of the enquiry into hepatitis C related discrimination.  Anti-Discrimination Board of New South Wales. Available at: http://www.lawlink.nsw.gov.au/adb.nsf/pages/hepcreport Accessed March 2004; 
    PubMedGoogle Scholar
  • 58 McNally S, Pitts M, Temple-Smith M. Now, later or never: when to refer a patient with hepatitis C. Paper presented at: 4th Australasian Conference on Hepatitis C, 2004 (abstract 65A) Canberra, Astralia;
    Google Scholar
  • 59 Falck-Ytter Y, Kale H, Mullen K D, Sarbah S A, Sorescu L, McCullough A J. Surprisingly small effect of antiviral treatment in patients with hepatitis C.  Ann Intern Med. 2002;  136 288-292
    PubMedGoogle Scholar
  • 60 Zickmund S, Hillis S L, Barnett M J, Ippolito L, LaBrecque D R. Hepatitis C virus-infected patients report communication problems with physicians.  Hepatology. 2004;  39 999-1007
    CrossrefPubMedGoogle Scholar
  • 61 Crofts N, Nigro L, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users.  Addiction. 1997;  92 999-1005
    CrossrefPubMedGoogle Scholar
  • 62 Selvey L A, Denton M, Plant A J. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus.  Aust N Z J Public Health. 1997;  21 102-104
    PubMedGoogle Scholar
  • 63 Alter M J, Margolis H S, Krawczynski K et al.. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.  N Engl J Med. 1992;  327 1899-1905
    CrossrefPubMedGoogle Scholar
  • 64 Mehta S H, Cox A, Hoover D R et al.. Protection against persistence of hepatitis C.  Lancet. 2002;  359 1478-1483
    CrossrefPubMedGoogle Scholar
  • 65 Micallef J, Jauncey M, Amin J et al.. Hepatitis C virus reinfection within a cohort of injecting drug users.  Hepatology. 2003;  38(suppl 1) 266A
    PubMedGoogle Scholar
  • 66 Bhattacharya R, Shuhart M C. Hepatitis C and alcohol: interactions, outcomes, and implications.  J Clin Gastroenterol. 2003;  36 242-252
    CrossrefPubMedGoogle Scholar
  • 67 Wiley T E, McCarthy M, Breidi L, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology. 1998;  28 805-809
    CrossrefPubMedGoogle Scholar
  • 68 Golub E T, Latka M, Hagan H et al.. Screening for Depressive Symptoms Among HCV-Infected Injection Drug Users: Examination of the Utility of the CES-D and the Beck Depression Inventory.  J Urban Health. 2004;  81 278-290
    PubMedGoogle Scholar
  • 69 Gleason O C, Yates W R, Isbell M D, Philipsen M A. An open-label trial of citalopram for major depression in patients with hepatitis C.  J Clin Psychiatry. 2002;  63(3) 194-198
    PubMedGoogle Scholar
  • 70 Kraus M R, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.  Aliment Pharmacol Ther. 2002;  16 1091-1099
    CrossrefPubMedGoogle Scholar
  • 71 Musselman D L, Lawson D H, Gumnick J F et al.. Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 961-966
    CrossrefPubMedGoogle Scholar
  • 72 Khan M H, Farrell G C, Byth K et al.. Which patients with hepatitis C develop liver complications?.  Hepatology. 2000;  31 513-520
    CrossrefPubMedGoogle Scholar
  • 73 Rey D, Carrieri M P, Spire B et al.. Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment.  J Urban Health. 2004;  81 48-57
    PubMedGoogle Scholar
  • 74 Poynard T, Imbert-Bismut F, Ratziu V et al.. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.  J Viral Hepat. 2002;  9 128-133
    CrossrefPubMedGoogle Scholar
  • 75 Imbert-Bismut F, Ratziu V, Pieroni L et al.. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.  Lancet. 2001;  357 1069-1075
    CrossrefPubMedGoogle Scholar
  • 76 Sylvestre D L. The impact of negative prognostic factors on hepatitis C treatment in recovering injection drug users.  Hepatology. 2002;  36(4 pt 2) 223A
    PubMedGoogle Scholar
  • 77 Sylvestre D L. Injection drug use and hepatitis C: from transmission to treatment.  Psychiatr Ann. 2003;  33 377-382
    PubMedGoogle Scholar
  • 78 Kresina T F, Normand J, Khalsa J, Mitty J, Flanigan T, Francis H. Addressing the need for treatment paradigms for drug-abusing patients with multiple morbidities.  Clin Infect Dis. 2004;  38(suppl 5) S398-S401
    CrossrefPubMedGoogle Scholar
  • 79 Krantz M J, Mehler P S. Treating opioid dependence. Growing implications for primary care.  Arch Intern Med. 2004;  164 277-288
    CrossrefPubMedGoogle Scholar
  • 80 Bouhnik A D, Chesney M, Carrieri P et al.. Nonadherence among HIV-infected injecting drug users: the impact of social instability.  J Acquir Immune Defic Syndr. 2002;  31(suppl 3) S149-S153
    PubMedGoogle Scholar
  • 81 Escaffre N, Morin M, Bouhnik A D et al.. Injecting drug users' adherence to HIV antiretroviral treatments: physicians' beliefs.  AIDS Care. 2000;  12 723-730
    CrossrefPubMedGoogle Scholar
  • 82 Moatti J P, Carrieri M P, Spire B, Gastaut J A, Cassuto J P, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group.  AIDS. 2000;  14 151-155
    PubMedGoogle Scholar
  • 83 Wood E, Montaner J S, Yip B et al.. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.  Can Med Assoc J. 2003;  169 656-661
    PubMedGoogle Scholar
  • 84 Conway B, Prasad J, Reynolds R et al.. Directly observed therapy for the management of HIV-infected patients in a methadone program.  Clin Infect Dis. 2004;  38(suppl 5) S402-S408
    CrossrefPubMedGoogle Scholar
  • 85 Lucas G M, Weidle P J, Hader S, Moore R D. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study.  Clin Infect Dis. 2004;  38(suppl 5) S409-S413
    CrossrefPubMedGoogle Scholar
  • 86 Altice F L, Mezger J A, Hodges J et al.. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication.  Clin Infect Dis. 2004;  38(suppl 5) S376-S387
    CrossrefPubMedGoogle Scholar
  • 87 Butler T G, Dolan K A, Ferson M J, McGuinness L M, Brown P R, Robertson P W. Hepatitis B and C in New South Wales prisons: prevalence and risk factors.  Med J Aust. 1997;  166 127-130
    PubMedGoogle Scholar
  • 88 Baillargeon J, Wu H, Kelley M J, Grady J, Linthicum L, Dunn K. Hepatitis C seroprevalence among newly incarcerated inmates in the Texas correctional system.  Public Health. 2003;  117 43-48
    CrossrefPubMedGoogle Scholar
  • 89 Vlahov D, Nelson K E, Quinn T C, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland.  Eur J Epidemiol. 1993;  9 566-569
    PubMedGoogle Scholar
  • 90 Sterling R K, Hofmann C M, Luketic V A et al.. Treatment of chronic hepatitis C virus in the Virginia department of corrections: can compliance overcome racial differences to response?.  Am J Gastroenterol. 2004;  99 866-872
    CrossrefPubMedGoogle Scholar
  • 91 Allen S A, Spaulding A C, Osei A M, Taylor L E, Cabral A M, Rich J D. Treatment of chronic hepatitis C in a state correctional facility.  Ann Intern Med. 2003;  138 187-190
    PubMedGoogle Scholar
  • 92 Villano S A, Vlahov D, Nelson K E, Lyles C M, Cohn S, Thomas D L. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.  J Clin Microbiol. 1997;  35 3274-3277
    PubMedGoogle Scholar
  • 93 Amin J, Kaye M, Skidmore S, Pillay D, Cooper D A, Dore G J. HIV and hepatitis C coinfection within the CAESAR study.  HIV Med. 2004;  5 174-179
    CrossrefPubMedGoogle Scholar
  • 94 Lincoln D, Petoumenos K, Dore G J. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy.  HIV Med. 2003;  4 241-249
    CrossrefPubMedGoogle Scholar
  • 95 Bonacini M, Lin H J, Hollinger F B. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus.  J Acquir Immune Defic Syndr. 2001;  26 340-344
    PubMedGoogle Scholar
  • 96 George S L, Gebhardt J, Klinzman D et al.. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests.  J Acquir Immune Defic Syndr. 2002;  31 154-162
    PubMedGoogle Scholar
  • 97 Thio C L, Nolt K R, Astemborski J, Vlahov D, Nelson K E, Thomas D L. Screening for hepatitis C virus in human immunodeficiency virus-infected individuals.  J Clin Microbiol. 2000;  38 575-577
    PubMedGoogle Scholar
  • 98 Sherman K E, O'Brien J, Gutierrez A G et al.. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections.  J Clin Microbiol. 1993;  31 2679-2682
    PubMedGoogle Scholar
  • 99 Eyster M E, Fried M W, Di Bisceglie A M, Goedert J J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.  Blood. 1994;  84 1020-1023
    PubMedGoogle Scholar
  • 100 Thomas D L, Shih J W, Alter H J et al.. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users.  J Infect Dis. 1996;  174 690-695
    CrossrefPubMedGoogle Scholar
  • 101 Anonymous . 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.  HIV Clin Trials. 2001;  2 493-554
    PubMedGoogle Scholar
  • 102 Eyster M E, Diamondstone L S, Lien J M, Ehmann W C, Quan S, Goedert J J. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study.  J Acquir Immune Defic Syndr. 1993;  6 602-610
    PubMedGoogle Scholar
  • 103 Darby S C, Ewart D W, Giangrande P L et al.. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.  Lancet. 1997;  350 1425-1431
    CrossrefPubMedGoogle Scholar
  • 104 Chung R T, Andersen J, Volberding P et al.. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.  N Engl J Med. 2004;  351 451-459
    CrossrefPubMedGoogle Scholar
  • 105 Torriani F J, Rodriguez-Torres M, Rockstroh J K et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.  N Engl J Med. 2004;  351 438-450
    CrossrefPubMedGoogle Scholar
  • 106 Bräu N. Treatment of chronic hepatitis C in HIV/HCV-coinfected patients in the era of pegylated interefron and ribavirin.  Semin Liver Dis. 2005;  25 33-51
    Article in Thieme ConnectPubMedGoogle Scholar
  • 107 Benhamou Y, Di Martino V, Bochet M et al.. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.  Hepatology. 2001;  34 283-287
    CrossrefPubMedGoogle Scholar
  • 108 Qurishi N, Kreuzberg C, Luchters G et al.. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection.  Lancet. 2003;  362 1708-1713
    CrossrefPubMedGoogle Scholar

 Dr.
Gregory J Dore

National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Level 2

376 Victoria Street, Darlinghurst

NSW, 2010 Australia

Email: gdore@nchecr.unsw.edu.au